Fresa, Alberto
 Distribuzione geografica
Continente #
NA - Nord America 383
EU - Europa 378
AS - Asia 204
SA - Sud America 5
AF - Africa 2
OC - Oceania 1
Totale 973
Nazione #
US - Stati Uniti d'America 378
IT - Italia 162
SG - Singapore 115
SE - Svezia 68
DE - Germania 34
ID - Indonesia 33
IE - Irlanda 33
CN - Cina 32
RU - Federazione Russa 17
FI - Finlandia 14
CZ - Repubblica Ceca 11
FR - Francia 10
IN - India 8
GB - Regno Unito 7
ES - Italia 6
CA - Canada 4
HK - Hong Kong 4
NL - Olanda 4
CO - Colombia 3
IR - Iran 3
KR - Corea 3
PL - Polonia 3
TR - Turchia 3
AT - Austria 2
CI - Costa d'Avorio 2
UA - Ucraina 2
AU - Australia 1
AZ - Azerbaigian 1
BE - Belgio 1
BO - Bolivia 1
BR - Brasile 1
EE - Estonia 1
IL - Israele 1
LT - Lituania 1
MC - Monaco 1
MX - Messico 1
PH - Filippine 1
PT - Portogallo 1
Totale 973
Città #
Singapore 98
Chandler 89
Ashburn 48
Rome 42
Florence 36
Dublin 33
Jakarta 33
New York 27
Milan 26
Moscow 14
Bremen 12
Princeton 12
Los Angeles 10
Boston 9
Munich 9
Chicago 8
Marseille 8
San Mateo 8
Wilmington 8
Beijing 7
Brno 7
Helsinki 7
Lappeenranta 7
Washington 6
North Hollywood 5
Pavia 5
Santa Clara 5
Brdo 4
London 4
Turin 4
Amsterdam 3
Arezzo 3
Bogotá 3
Central 3
Fairfield 3
Nuremberg 3
Pune 3
San Marzano sul Sarno 3
Seoul 3
Seville 3
Abidjan 2
Afragola 2
Ankara 2
Bangalore 2
Cattolica 2
Frankfurt am Main 2
Garden City 2
Gdansk 2
Guangzhou 2
Livorno 2
Michigan City 2
Napoli 2
Norwalk 2
Ottawa 2
Redwood City 2
Shanghai 2
Vienna 2
Vigo 2
Woodbridge 2
Zanjan 2
Albuquerque 1
Augusta 1
Baku 1
Berlin 1
Brussels 1
Busto Arsizio 1
Chiswick 1
Clifton 1
Dearborn 1
Forest City 1
Foshan 1
Fuyang 1
Gragnano 1
Haikou 1
Hefei 1
Hong Kong 1
Houston 1
Hyderabad 1
Jacksonville 1
Jiaxing 1
Kashan 1
La Paz 1
Lisbon 1
Lu'an 1
Manila 1
Monaco 1
Mumbai 1
Nizhniy Novgorod 1
Ottaviano 1
Paris 1
Phoenix 1
Santarcangelo di Romagna 1
Seattle 1
Segni 1
Shijiazhuang 1
Stockholm 1
Tallinn 1
Toronto 1
Vancouver 1
Vinhedo 1
Totale 701
Nome #
Autologous stem cell transplantation as bridging therapy followed by CD19 CAR-T cells in relapsed-refractory large B cell lymphoma. 76
Subcutaneous immunoglobulins in chronic lymphocytic leukemia with secondary antibody deficiency. A monocentric experience during Covid-19 pandemics 63
the concomitance of lymphoma and breast carcinoma in the bone 57
Front-Line Therapy for Elderly Chronic Lymphocytic Leukemia Patients: Bendamustine Plus Rituximab or Chlorambucil Plus Rituximab? Real-Life Retrospective Multicenter Study in the Lazio Region 49
VEGF and IL-6 Correlation in POEMS: A Potential Upcoming Marker of Active Disease and Early Autologous BMT Response 49
Non-overt disseminated intravascular coagulopathy associated with the first obinutuzumab administration in patients with chronic lymphocytic leukemia 48
Treatment options for elderly/unfit patients with chronic lymphocytic leukemia in the era of targeted drugs: A comprehensive review 46
Do age, fitness and concomitant medications influence management and outcomes of CLL patients treated with ibrutinib? 45
The concomitance of lymphoma and breast carcinoma in the bone 44
Autoimmune hemolytic anemia in chronic lymphocytic leukemia: A comprehensive review 41
Endothelial activation predicts disseminated intravascular coagulopathy, cytokine release syndrome and prognosis in patients treated with anti-CD19 CAR-T 40
Purging with chlorambucil to prevent infusion-related reaction before obinutuzumab administration: A monocentric pilot experience 39
Coexisting conditions and concomitant medications do not affect venetoclax management and survival in chronic lymphocytic leukemia 34
Unselected donor-derived hematopoietic stem cells boost for Chimeric Antigen Receptor T-cell associated hematotoxicity 34
What Does Atypical Chronic Lymphocytic Leukemia Really Mean? A Retrospective Morphological and Immunophenotypic Study 31
Endothelial activation predicts disseminated intravascular coagulopathy, cytokine release syndrome and prognosis in patients treated with anti-CD19 CAR-T cells 31
Non-overt disseminated intravascular coagulopathy associated with the first obinutuzumab administration in patients with chronic lymphocytic leukemia 29
Clinical and molecular features of familial chronic lymphocytic leukemia: a pilot monocentric study 28
Richter transformation in Chronic Lymphocytic Leukemia 27
Obinutuzumab plus chlorambucil versus ibrutinib in previously untreated chronic lymphocytic leukemia patients without TP53 disruptions: A real-life CLL campus study 24
Relative dose intensity of obinutuzumab-chlorambucil in chronic lymphocytic leukemia: a multicenter Italian study 23
Thrombotic and bleeding complications in patients with chronic lymphocytic leukemia and severe COVID-19: a study of ERIC, the European Research Initiative on CLL 22
Acute graft versus host disease 1976-2020: reduced incidence and predictive factors 20
Effect of HLA mismatch on post-transplant infections in allogeneic hematopoietic stem cell transplantation with PTCy-based GvHD prophylaxis 19
Correspondence in reference to the previously published manuscript: Reduction of cycles of bendamustine plus rituximab therapy in the cases with good response for indolent B-cell lymphomas 19
Continuous treatment with Ibrutinib in 100 untreated patients with TP53 disrupted chronic lymphocytic leukemia: A real-life campus CLL study 17
Venetoclax infectious risk score to identify patients with chronic lymphocytic leukemia at high infectious risk during venetoclax treatment: A multicenter SEIFEM study 15
Hematopoiesis and immune reconstitution after CD19 directed chimeric antigen receptor T‐cells (CAR‐T): A comprehensive review on incidence, risk factors and current management 11
Clinical and molecular features of familial chronic lymphocytic leukemia: a pilot monocentric study 9
Treatment Sequencing and Outcome of Chronic Lymphocytic Leukemia Patients Treated at Fondazione Policlinico Universitario Agostino Gemelli IRCCS: A Thirty-Year Single-Center Experience 9
The clinical experience of compassionate use program for avapritinib: implications for drug positioning in the therapeutic scenario of systemic mastocytosis 8
COVID-19 in patients with Chronic Lymphocytic Leukemia treated with venetoclax: what is the role of anti-CD20 antibody? 7
Lymphadenopathy as a predictor of progression during venetoclax treatment in chronic lymphocytic leukemia. A campus chronic lymphocytic leukemia study 6
Role of microRNAs in Chronic Lymphocytic Leukemia 4
Totale 1.024
Categoria #
all - tutte 7.678
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 7.678


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202017 0 0 0 0 0 5 1 0 0 0 9 2
2020/20218 0 0 0 0 1 0 2 0 2 0 3 0
2021/202290 0 3 7 2 8 0 1 10 6 0 35 18
2022/2023314 38 37 14 37 25 28 13 23 48 17 31 3
2023/2024374 6 68 22 37 16 57 32 21 2 27 31 55
2024/2025221 22 19 58 56 66 0 0 0 0 0 0 0
Totale 1.024